Singapore Paincare (SGX:FRQ) disclosed a qualified opinion from auditors BDO LLP for its financial statements for the year ended June 30, 2024, according to a Thursday filing on the Singapore Exchange.
The group's goodwill, valued at $13.5 million, was assessed for impairment using a value-in-use method, with no impairment loss recognized. The assessment of investments in subsidiaries, totaling around $5 million, also showed no impairment loss.
Additionally, the fair value of financial assets held by the group's joint venture, Singapore Paincare Capital, was recorded at about $8.8 million, contributing to a fair value gain of $578,000.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。